Tumor vascular endothelium antigen

The term "tumor vascular endothelium antigen" does not refer to a single well-defined molecular entity but rather encompasses a set of proteins differentially expressed on the surface of endothelial cells lining blood vessels within tumors. These so-called "tumor-associated endothelial cells" exhibit distinct phenotypes compared to normal tissue endothelium—characterized by altered gene expression profiles supporting increased angiogenesis, metabolic activity, matrix remodeling capacity, and immunomodulatory properties. Commonly studied examples include upregulated markers such as CD34 (stem/progenitor marker), CD105/endoglin (TGF-beta co-receptor), integrins like CD61/beta3 integrin involved in migration and survival signaling, as well as functional proteins like VCAM1 that mediate leukocyte recruitment. These antigens are considered promising therapeutic targets because they are accessible from the bloodstream and play critical roles in sustaining abnormal vessel growth required for solid tumors' progression. However, their heterogeneity across cancer types—and even within individual tumors—poses challenges for drug development. Antiangiogenic drugs currently approved often target broad classes such as VEGF receptors rather than unique "tumor vascular endothelium antigens." Research continues into identifying more selective markers that could enable precise delivery of therapeutics or imaging agents. Because "tumor vascular endothelium antigen" is an umbrella term rather than a canonical name for one molecule—and may be used inconsistently—it is important to specify which particular protein(s) are being referenced when seeking structured data.

Other names

Tumor endothelial cell antigenTumor-associated endothelial cell markerTumor endothelium markerTEC antigen (less common, context-dependent)

Drugs targeting these antigens typically act by inhibiting angiogenesis through blockade of growth factor signaling pathways such as VEGF/VEGFR, interfering with vessel maturation and function, or modulating immune cell infiltration by altering the expression of adhesion molecules like VCAM1.